Bizikova Petra, Papich Mark G, Olivry Thierry
Department of Clinical Sciences, College of Veterinary Medicine, Veterinary Teaching Hospital, North Carolina State University, 4700 Hillsborough Street, Raleigh, NC 27606, USA.
Vet Dermatol. 2008 Dec;19(6):348-57. doi: 10.1111/j.1365-3164.2008.00697.x. Epub 2008 Oct 11.
Pharmacokinetic parameters of hydroxyzine and its active metabolite cetirizine were determined after oral and intravenous administration of 2 mg kg(-1) of hydroxyzine to six healthy dogs. Plasma drug levels were determined with high-pressure liquid chromatography. Pharmacodynamic studies evaluated the suppressive effect on histamine and anticanine IgE-mediated cutaneous wheal formation. Pharmacokinetic and pharmacodynamic correlations were determined with computer modelling. The mean systemic availability of oral hydroxyzine was 72%. Hydroxyzine was rapidly converted to cetirizine regardless of the route of administration. The mean area-under-the-curve was eight and ten times higher for cetirizine than hydroxyzine after intravenous and oral dosing, respectively. After oral administration of hydroxyzine, the mean peak concentration of cetirizine was approximately 2.2 microg mL(-1) and that of hydroxyzine 0.16 microg mL(-1). The terminal half-life for cetirizine varied between 10 and 11 h after intravenous and oral administration of hydroxyzine. A sigmoidal relationship was fit to the data comparing cetirizine plasma concentration to wheal suppression. Maximum inhibition (82% and 69% for histamine and anticanine IgE-mediated skin reactions, respectively) was observed during the first 8 h, which correlated with a plasma concentration of cetirizine greater than 1.5 microg mL(-1). Pharmacological modelling suggested that increasing either hydroxyzine dosages or frequencies of administration would not result in histamine inhibition superior to that obtained with twice daily hydroxyzine at 2 mg kg(-1). In conclusion, there was rapid conversion of hydroxyzine to cetirizine. The reduction of wheal formation appeared almost entirely due to cetirizine. Pharmacodynamic modelling predicted that maximal antihistamine effect would occur with twice daily oral administration of hydroxyzine at 2 mg kg(-1).
给6只健康犬口服和静脉注射2mg/kg的羟嗪后,测定了羟嗪及其活性代谢物西替利嗪的药代动力学参数。采用高压液相色谱法测定血浆药物水平。药效学研究评估了对组胺和抗犬IgE介导的皮肤风团形成的抑制作用。通过计算机建模确定药代动力学和药效学相关性。口服羟嗪的平均全身利用率为72%。无论给药途径如何,羟嗪都能迅速转化为西替利嗪。静脉注射和口服给药后,西替利嗪的平均曲线下面积分别比羟嗪高8倍和10倍。口服羟嗪后,西替利嗪的平均峰浓度约为2.2μg/mL,羟嗪为0.16μg/mL。静脉注射和口服羟嗪后,西替利嗪的终末半衰期在10至11小时之间变化。将西替利嗪血浆浓度与风团抑制进行比较的数据拟合为S形关系。在最初8小时内观察到最大抑制(组胺和抗犬IgE介导的皮肤反应分别为82%和69%),这与西替利嗪血浆浓度大于1.5μg/mL相关。药理模型表明,增加羟嗪剂量或给药频率不会导致组胺抑制效果优于每日两次给予2mg/kg羟嗪所获得的效果。总之,羟嗪能迅速转化为西替利嗪。风团形成的减少几乎完全归因于西替利嗪。药效学模型预测,每日两次口服2mg/kg羟嗪将产生最大抗组胺作用。